Pentixapharm Holding AG (ETR:PTP) | Finanzwire

Basculer en Français

10670	Companies
227495	Keywords
155822	Articles
120436	Press releases

Headlines Articles Press releases Pentixapharm Holding AG

Home
Companies
Pentixapharm Holding AG

BRIEF

published on 07/01/2026 at 12:10, 2 hours 31 minutes ago

Pentixapharm Holding AG Plans Rights Issue to Raise EUR 20.4 Million

Capital Increase Rights Issue Subscription Price PANDA Phase 3 Study Eckert Wagniskapital
PRESS RELEASE

published on 07/01/2026 at 12:05, 2 hours 36 minutes ago

EQS-Adhoc: Pentixapharm Holding AG: Resolves on Rights Issue with an Offering Volume of up to Appr. EUR 20.4 Million; Major Shareholder Eckert Wagniskapital Commits to Fully Exercise Its Subscription Rights
Pentixapharm Holding AG resolves on rights issue worth up to EUR 20.4 million; Eckert Wagniskapital to fully exercise subscription rights for new shares, supporting corporate development and PANDA Phase 3 study

Rights Issue Subscription Rights Pentixapharm Holding AG PANDA Phase 3 Study Eckert Wagniskapital
BRIEF

published on 06/09/2026 at 08:09, 22 days 6 hours ago

Pentixapharm's [68Ga]Ga-PentixaFor: A Potential Game-Changer in Diagnostics

FDA Approval Pentixapharm [68Ga]Ga-PentixaFor Primary Hyperaldosteronism PET/CT Diagnostics
BRIEF

published on 06/09/2026 at 08:05, 22 days 6 hours ago

Pentixapharm Secures FDA IND Clearance for Phase 3 PANDA Study

FDA Clearance Phase 3 Study Cardiovascular Diagnostics Primary Aldosteronism Patient Stratification
PRESS RELEASE

published on 06/09/2026 at 08:04, 22 days 6 hours ago

[68Ga]Ga-PentixaFor in Primary Aldosteronism: Billion-Dollar Potential in an Underserved Mass Market
Pentixapharm Holding AG receives FDA approval for Phase III study on [68Ga]Ga-PentixaFor in Primary Aldosteronism, targeting billion-dollar revenue potential in underserved market

FDA Approval Market Potential Primary Aldosteronism Pentixapharm Holding AG [68Ga]Ga-PentixaFor
PRESS RELEASE

published on 06/09/2026 at 08:00, 22 days 6 hours ago

Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program
Pentixapharm receives FDA clearance for Phase 3 PANDA study of novel cardiovascular diagnostic program targeting resistant hypertension and primary aldosteronism

FDA Clearance Hypertension Cardiovascular Diagnostics Pentixapharm Phase 3 PANDA Study
BRIEF

published on 06/09/2026 at 07:50, 22 days 6 hours ago

Pentixapharm Holding AG Advances with FDA Approval and Capital Increase Plan

FDA Approval Capital Increase Primary Aldosteronism PANDA Study BaFin Review
PRESS RELEASE

published on 06/09/2026 at 07:45, 22 days 6 hours ago

EQS-Adhoc: Pentixapharm Holding AG: FDA grants “Study May Proceed” for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10 Million Shares; BaFin Financial Reporting Enforcement Review
Pentixapharm Holding AG receives FDA clearance for Phase 3 study, plans capital increase of up to 10 million shares with subscription rights, and faces BaFin financial review

FDA Clearance Capital Increase Phase 3 Study Pentixapharm Holding AG BaFin Review
BRIEF

published on 05/11/2026 at 08:05, 1 month 21 days ago

Pentixapharm Submits IND to FDA for Phase 3 PANDA Study

Pentixapharm Precision Diagnostics FDA IND Submission Phase 3 PANDA Cardiovascular Imaging
PRESS RELEASE

published on 05/11/2026 at 08:00, 1 month 21 days ago

Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic
Pentixapharm submits IND to FDA for Phase 3 PANDA study of CXCR4-targeted cardiovascular diagnostic, aiming at precision diagnostics in primary aldosteronism

Pentixapharm IND Submission Phase 3 PANDA Study CXCR4-targeted Cardiovascular Diagnostic

1 2 ... 8

Accesswire

Published on 07/01/2026 at 14:30, 12 minutes ago

AIAI Holdings' MediGuide Launches Digital Platform
Published on 07/01/2026 at 13:30, 1 hour 12 minutes ago

Sidney Resources Corporation Appoints Former Idaho Governor C.L. "Butch" Otter as Chairman of the Board
Published on 07/01/2026 at 13:00, 1 hour 42 minutes ago

Fox River Issues Shares Pursuant to Exploration Agreement in Connection with Impending Arrangement
Published on 07/01/2026 at 03:15, 11 hours 27 minutes ago

GLG Life Tech Corporation Announces 2026 AGM Voting Results
Published on 07/01/2026 at 01:00, 13 hours 42 minutes ago

Onco-Innovations Announces Term Sheet for Notional CAD$5 Million Performance-Based Funding Arrangement and Amendments to Previously Announced Financing

View all ACCESSWIRE

EQS Group

Published on 07/01/2026 at 14:30, 11 minutes ago

#LUXMyWill: Beauty Brand LUX Turns '#BuryMeInThis' From Social Media Trend Into Legal Declaration
Published on 07/01/2026 at 13:57, 44 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 07/01/2026 at 13:55, 46 minutes ago

AdJane Reports First Clinical Validation of its OMV Vaccine Platform Inducing Mucosal Immunity in Humans
Published on 07/01/2026 at 13:54, 47 minutes ago

Amundi Physical Metals plc: Final Terms
Published on 07/01/2026 at 13:43, 58 minutes ago

ams OSRAM closes the sale of its non‑optical analog/mixed-signal sensor business to Infineon for EUR 570 million in cash

Les Echos

Published on 07/01/2026 at 08:45, 5 hours 57 minutes ago

Air Liquide invests over 170M USD in the U.S. to support SK hynix’s ambition to build a global AI memory ecosystem
Published on 07/01/2026 at 07:00, 7 hours 42 minutes ago

BIOPHYTIS REPORTS ITS PROVISIONAL FINANCIAL RESULTS AND PROVIDES ITS STRATEGIC OUTLOOK
Published on 06/30/2026 at 20:52, 17 hours 49 minutes ago

Number of shares and voting rights - May 2026 (In French only)
Published on 06/30/2026 at 18:59, 19 hours 42 minutes ago

SUEZ has successfully completed a €600 million green bond issuance
Published on 06/30/2026 at 17:45, 20 hours 57 minutes ago

Carrefour completes the sale of Carrefour Romania to Paval Holding

View all LES ECHOS COMFI WIRE